Consensus and controversy of liquid biopsy using circulating tumour DNA (ctDNA) for molecular residual disease detection in colorectal cancer
Summary Circulating tumour DNA (ctDNA) detection after curative-intent treatment is one of the strongest prognostic biomarkers in colorectal cancer (CRC), but its clinical utility remains incompletely established. Randomised trials have shown that ctDNA-informed management can reduce adjuvant chemotherapy exposure in s...